Different Patterns of Autoantibody Secretion by Peripheral Blood Mononuclear Cells in Autoimmune Nodopathies
Sophia Rohrbacher,Sabine Seefried,Beate Hartmannsberger,Rosa Annabelle,Luise Appeltshauser,Friederike A Arlt,Dirk Brämer,Christian Dresel,Johannes Dorst,Zeynep Elmas,Christiana Franke,Christian Geis,Tobias Högen,Sabine Krause,Martin Marziniak,Mathias Mäurer,Harald Prüss,Florian Schoeberl,Bertold Schrank,Claudia Steen,Helena Teichtinger,Andrea Thieme,Lena Wessely,Alma Zernecke,Claudia Sommer,Kathrin Doppler
DOI: https://doi.org/10.1212/NXI.0000000000200295
Abstract:Background and objectives: Autoimmune nodopathies with antibodies against the paranodal proteins show a distinct phenotype of a severe sensorimotor neuropathy. In some patients, complete remission can be achieved after treatment with rituximab whereas others show a chronic course. For optimal planning of treatment, predicting the course of disease and therapeutic response is crucial. Methods: We stimulated peripheral blood mononuclear cells in vitro to find out whether secretion of specific autoantibodies may be a predictor of the course of disease and response to rituximab. Results: Three patterns could be identified: In most patients with anti-Neurofascin-155-, anti-Contactin-1-, and anti-Caspr1-IgG4 autoantibodies, in vitro production of autoantibodies was detected, indicating autoantigen-specific memory B cells and short-lived plasma cells/plasmablasts as the major source of autoantibodies. These patients generally showed a good response to rituximab. In a subgroup of patients with anti-Neurofascin-155-IgG4 autoantibodies and insufficient response to rituximab, no in vitro autoantibody production was found despite high serum titers, indicating autoantibody secretion by long-lived plasma cells outside the peripheral blood. In the patients with anti-pan-Neurofascin autoantibodies-all with a monophasic course of disease-no in vitro autoantibody production could be measured, suggesting a lack of autoantigen-specific memory B cells. In some of them, autoantibody production by unstimulated cells was detectable, presumably corresponding to high amounts of autoantigen-specific plasmablasts-well in line with a severe but monophasic course of disease. Discussion: Our data suggest that different B-cell responses may occur in autoimmune nodopathies and may serve as markers of courses of disease and response to rituximab.